We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > News > Science & Health > Content Piece

MyDx to Support Study on the Impacts of Cannabis Use in HIV Patients

Published: Oct 18, 2018   
Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

MyDx, a leader in science-based cannabis health technologies, has announced that the University of Florida will be using their flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.

“With this study, we are taking an additional step in solidifying our position as a leader in science-based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long-term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx.  “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.” 

We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.   

This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.  

Marijuana and Potential Long-term Effects Study Goals

The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation. 

The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years. 

During a visit, participants will be asked to:

• Give a small blood sample

• Give a small urine sample

• Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood

• Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad

The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects). 

The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.  

The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit.

This article has been republished from materials provided by MyDx. Note: material may have been edited for length and content. For further information, please contact the cited source.


Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter